A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 7, 2016, Pages 1881-1884

  Khan, David D ^a   Friberg, Lena E ^a   Nielsen, Elisabet I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT;

ABSORPTION RATE CONSTANT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM DRUG EFFECT; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIPLE DRUG DOSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SIMULATION; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION; ANIMAL; COMPUTER SIMULATION; DISEASE MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; TIME FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 84979035677     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw057     Document Type: Article

References (15)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2
2. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7
3. Mouton JW, Brown DF, Apfalter P et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012; 18: E37-45
4. Drusano GL, Preston SL, Hardalo C et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45: 13-22
5. Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 2013; 65: 1053-90
6. Nielsen EI, Cars O, Friberg LE. Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokineticpharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 1571-9
7. Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011; 55: 4619-30
8. Bergen PJ, Bulitta JB, Forrest A et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010; 54: 3783-9
9. Dudhani RV, Turnidge JD, Coulthard K et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54: 1117-24
10. Mohamed AF, Cars O, Friberg LE. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. J Antimicrob Chemother 2014; 69: 1350-61
11. Karvanen M. Optimization of colistin dosage in the treatment of multiresistant Gram-negative infections. PhD Thesis. Uppsala University, 2013
12. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol 2013; 51: 1678-84
13. Sader HS, Rhomberg PR, Flamm RK et al. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagn Microbiol Infect Dis 2012; 74: 412-4
14. Cheah SE, Wang J, Nguyen VTet al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 2015; 70: 3291-7
15. Beal S, Sheiner LB, Boeckmann A et al. NONMEM User's Guides (1989-2009). Ellicott City, MD: Icon Development Solutions, 2009